Our reflections on the use of PET/CT to assess treatment response following neoadjuvant treatment for Stage III melanoma. A short communication reflecting on past, present and future on the field. Still much to be explored @TJH0828 https://t.co/7bqkopqIrG

Is PET-CT a good predictor of the pathological response post neoadjuvant treatment in Stage III melanoma? We report on a cohort of real-world patients treated with immunotherapy alone or in combination with targeted therapy. @AnnSurgOncol @TJH0828

Ending the melanoma session with data on treatment for BRAFm melanoma: the final DREAMseq data still showing that upfront ipi/nivo is superior to targeted therapy. For symptomatic brain mets, IO+TT combo improves PFS but not OS, maybe we should try quadruple therapy next #ASCO25

More neoadjuvant data, hard to choose from all these great options: anti TIM and TLR9 agonists could both enhance the pCR rate for stage III melanoma. TLR9 has higher response rates, yet harder to use with IT injections and 25% of patients not competing treatment course.#ASCO25

Great presentation by @TJH0828 on the promising results of the NEOACTIVATE arm C trial of anti TIGIT + anti PDL1 for clinical stage III melanoma. Correlative studies to follow in hope of identifying predictive biomarkers for better treatment tailoring. #ASCO25 @SU2C @MayoClinic

Neoadjuvant-adjuvant pembro for stage IIB/C melanoma is feasible and safe, yet RFS and DMFS are exactly the same as KN716. Interesting signal with decreased SLN positivity in clinical stage IIC patients, possible worth further exploration. #ASCO25

Unfortunately the study of adjuvant targeted therapy for stage IIB/C was terminated early, and only descriptive data on 110 patients is available. Numerically there is a difference, still not enough to act on for patients who aren't candidates for adjuvant immunotherapy. #ASCO25

Starting the closing melanoma session with the 098 study results - adding rela to nivo does not improve RFS or DMFS. Still need to better refine our patient selection for adjuvant therapy in stage III melanoma. #ASCO25 @ProfGLongMIA

Finishing the morning rapid abstract session with very promising results of OBX115, a modified TIL product which doesn't require IL-2 or high dose LD chemotherapy. Waiting for the phase 3 trial. #ASCO25

Interesting data on neoadjuvant single dose of ipi 3 + nivo 1 for stage III melanoma. Same pCR rate as seen with two doses of flipped dose and low irAE rate. Still looking for the imaging biomarker that will help us de-escalate the surgery. #ASCO25

Another agent hopefully being added soon to our growing uveal melanoma arsenal, first results of the ADC GQ/11 direct inhibitor. Promising responses and very little toxicity. #ASCO25

Great data on the combination of triplet immunotherapy with IL-6 blockade as first line for metastatic melanoma, showing an ORR of 63% and only 12% of G3+ irAEs during the first 24 weeks of treatment. Very interesting signal, prevention is the future of ICI combinations #ASCO25

Nothing like finishing another great day at #ASCO25 with the checkpoints

First day for me at #ASCO25 , enjoyed connecting with friends and this nice presentation on the phase I outcomes of PRAME directed TCR T therapy, especially the melanoma cohort. Very promising results even though patient dropout was significant, can't wait for the phase III trial

3-Year OS for nivo/rela is improved when compared to nivo, yet the HR is 0.80 with CI upper level of 0.99. Also, PFS seems to significantly decrease over time. While this combination has a place, I don't see it as equivalent to ipi-nivo for fit patients https://t.co/K4QuJ404KW

While it is the same familiar data, the advantage of ipi-nivo over nivo monotherapy remains constant across trials. Still the gold standard for fit patients with #Melanoma and especially for those with liver and brain mets.@ProfGLongMIA

Patients who recurred on adjuvant nivo do poorly in the metastatic setting, with a surprisingly low PFS and OS on ipi-nivo. We need a better strategy for these primary resistant #Melanoma , maybe TILs +/-ipi?

Great piece in JCO about the usefulness of PD-L1 staining as a decision tool for single vs. combo #Immunotherapy in patients with metastatic #Melanoma . I definitely agree that the decision should be based on tumor characteristics, patient's background and their preferences

48% cure rate with adjuvant nivo for fully resected stage III/IV #Melanoma , consistent benefit over ipi and over placebo. Encouraging, yet the benefit seems more modest for BRAFm patients, still waiting to see TT vs. IO adjuvant trial for BRAFm patients🤔

Great presentation by my amazing twitterless mentor Matt Block on the clinical and correlative results of the neoadjuvant trial examining the combination of immunotherapy and targeted therapy for resectable stage 3 #Melanoma . Great clues for further ongoing investigation🧑‍🔬